Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday. Puneet Souda’s ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

We plan to accelerate growth in 2025, and our long-term outlook remains strong,” said Kevin Conroy, chairman and CEO.

Exact Sciences stock tumbled late Tuesday after the company cut its outlook and posted weaker-than-expected results.Shares of ...

Thanks, operator. Thank you for joining us for Exact Sciences' third-quarter 2024 conference call. On the call today are ...

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.

“The Exact Sciences’ team is helping eradicate cancer while strengthening our platform and growing our business efficiently,” said Kevin Conroy, CEO of Exact Sciences. “During the third quarter, we ...